Cero Therapeutics

5 articles about Cero Therapeutics

• CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

  3/7/2024

  CERo Therapeutics Holdings, Inc., today announced the publication in Clinical Cancer Research , a journal of the American Association for Cancer Research, a paper titled “ Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia.”

• Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination

  2/14/2024

  Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms announced that their previously announced business combination has closed, resulting in CERo becoming a publicly-traded company.

• CERo Therapeutics’ Multifunctional CER T Cells Synergize with Standard-of-Care Small Molecule Anti-Tumor Inhibitors Across Hematologic and Solid Tumor Models

  5/2/2022

  CERo Therapeutics, Inc., today announced new preclinical data to be presented at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) demonstrating significant anti-tumor effects of chimeric engulfment receptor (CER) T cells when combined with small molecule therapies in both hematologic and solid tumor models.

• CERo Therapeutics’ Novel Chimeric Engulfment Receptor T Cells Exhibit Multifunctional Properties and Enhanced Tumor Killing

  11/12/2021

  CERo Therapeutics, Inc., a biopharmaceutical company pioneering the development of novel autologous engineered immune cell therapies, presented the results from preclinical in vitro studies describing the characterization of novel chimeric engulfment receptor T cells.

• CERo Therapeutics Expands Leadership Team with Experts in Cell Therapy Development

  4/15/2021

  -- Remus Vezan, M.D., Ph.D., joins as CMO to lead clinical development -- -- John Rossi will direct translational research efforts --